IBA posts mixed 2018 financial results
Proton therapy developer Ion Beam Applications (IBA) posted mixed results for...Read more on AuntMinnie.comRelated Reading: IBA opens cyclotron center in India IBA's proton therapy system up and running in Japan IBA receives Brazil's OK for proton therapy system IBA wins Singapore contract Purchase delays affect IBA's 6-month results
This article presents an overview of current indications for PT with emphasis on tumors in the head and neck region and the base of skull. Furthermore, a summary and discussion of relevant results and current developments are included. MATERIALS AND METHODS: The work comprises an evaluation of relevant studies and an overview of current issues related to PT of tumors in the areas of the head, neck, and base of skull. RESULTS: Overall, the studies on PT show promising results. In addition to dosimetric studies, clinical studies also point to advantages of PT, especially with regard to the reduction of side effects. ...
Proteus 235 The Proton Therapy System - Proteus 235 (brand names: Proteus Plus and Proteus ONE) is a medical device designed to produce and deliver a proton beam for the treatment of patients with localized tumors and other conditions susceptible to treatment by radiation.
CONCLUSION: Both full plan adaptation and simple dose restoration can increase OAR sparing besides better conforming to the target criteria compared to robust treatment planning. PMID: 32777242 [PubMed - as supplied by publisher]
CONCLUSIONS: Visual acuity decline following radiotherapy for intracranial malignancies in children is rare. A dose of approximately 56 GyRBE to 0.1 cm3 results in an approximately 5% risk of visual acuity decline for children with suprasellar or optic pathway tumors. A dose to 0.1 cm3 of 56 GyRBE appears to be safe for children with tumors elsewhere in the brain. PMID: 32762400 [PubMed - as supplied by publisher]
This study compares a robust planning strategy to two online-adaptive IMPT strategies to determine the benefit of online adaptation.
Compared to radiotherapy using photons, the superior beam properties of protons can be translated into two main strategies to obtain a clinical benefit: 1) dose escalation to improve local tumor control without increasing the risk of unacceptable radiation-induced toxicity, or 2) the sparing of healthy tissues with equivalent target dose to reduce the risk of radiation-induced side effects with similar tumor control. For the latter group of indications, the model-based approach was developed [1,2].
CONCLUSIONS: 4D dose reconstruction and accumulation enables the clinical estimation of actual exhibited interplay and motion effects. In the patients considered here, the loss of homogeneity caused by interplay and organ motion did not show systematic pattern and smeared out throughout the course of fractionated PBS-PT treatment. Dose degradation due to anatomical changes showed to be more severe and triggered treatment adaptations for five patients. PMID: 32768509 [PubMed - as supplied by publisher]
CONCLUSION: Model-based selection of patients with HNC for proton therapy is clinically feasible. Approximately one third of HNC patients qualify for protons and these patients have the highest probability to benefit from protons in terms of toxicity prevention. PMID: 32768508 [PubMed - as supplied by publisher]
Pencil beam scanned proton therapy (PBS PT) treatments of intrathoracic targets are associated with significant uncertainty. Treatment quality may be compromised by setup errors, range uncertainties, respiratory motion baseline shifts, anatomical changes, delivery inaccuracies and motion of various sources (e.g. respiration, cardiac motion, swallowing, etc.). More specifically, the relative motion between a thoracic target volume and the scanning proton beam can cause deviation of the delivered dose from the planned dose and is referred to as the interplay effect.